Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?

Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials

“…5 However, the FDA approved the use of a fixed-dose combination of memantine hydrochloride extended-release and donepezil hydrochloride (ie, Namzaric) for moderate-to-severe AD in 2014. 6 Several meta-analyses have been conducted to make definitive conclusion on the effectiveness of combination therapy, 7e9 although these studies were usually lacked a completed literature search, and misinterpretation of measurement scale. 10 The findings of these metaanalyses were inconclusive.…”

Palladium‐Catalyzed Pyrazole‐Directed sp3 C−H Bond Arylation for the Synthesis of β‐Phenethylamines

“…Pyrazolyladamantane 3-4 was arylated in 53% yield to give product 3-5 . Compound 3-6 , which contains the dimethyladamantane moiety present in memantine, [15] reacted well to give arylation product 3-7 in 45% yield. Interestingly, 2-adamantyl-substituted pyrazole 3-8 was reactive and afforded three compounds.…”

Long-Term Effects Of Combined Treatment With Memantine And Donepezil On Alzheimer's Disease Patients: 72-Week Study

“…Cholinesterase inhibitors (ChEIs) and N-methyl D-aspartate (NMDA) receptor antagonists are the two most prevalent types of medicine approved by the U.S. Food and Drug Administration. When the metabolizing enzyme is suppressed, acetylcholine (Ach) activity is increased, and cognitive functions improve in turn [6]. In addition, NMDA receptor antagonists regulate glutamatergic neurons activities that facilitate synaptic plasticity and neuronal growth and differentiation, thereby enhancing cognition, learning, and memory [1,7].…”